Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

This AI company isn't yet living up to the hype. Let's discuss Recursion Pharmaceuticals' performance over the past four years and whether the company can deliver solid returns in the future. It can ...

A variation of a puzzle called the “pick-up sticks problem” asks the following question: If I have some number of sticks with random lengths between 0 and 1, what are the chances that no three of ...

Community driven content discussing all aspects of software development from DevOps to design patterns. Good programmers need to create code that efficiently solves problems, using various methods. A ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...

Fibonacci offers specialized software and services to financial institutions Fibonacci’s revenue will now succeed €210 million Equinox has acquired Quid Group in 2019 Fibonacci Group, which is backed ...